Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6996483 | 0.89 | PTGS2 (0.38) | PGRPTGS1PTGS2 | |
| SCHEMBL6995349 | 0.89 | PGR (0.40) | PGRGSK3BESR2 | |
| SCHEMBL6998907 | 0.89 | PGR (0.40) | PGRGSK3BPTGS1PTGS2 | |
| SCHEMBL7002130 | 0.89 | PTGS2 (0.42) | PGRPTGS1PTGS2 | |
| SCHEMBL6995081 | 0.88 | PGR (0.36) | PGRGSK3BPTGS1PTGS2 | |
| SCHEMBL6997965 | 0.86 | PGR (0.38) | PGRPTGS1PTGS2 | |
| SCHEMBL6999681 | 0.86 | PTGS2 (0.37) | PGRPTGS1PTGS2 | |
| SCHEMBL6995269 | 0.84 | GSK3B (0.51) | PGRGSK3BESR2PTGS1PTGS2 | |
| SCHEMBL7001628 | 0.83 | PGR (0.34) | PGRPTGS1PTGS2 | |
| SCHEMBL7002303 | 0.82 | PGR (0.35) | PGRPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | claimed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | claimed |
| EP-1109799-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2001-06-27 | — | — | EP | claimed |
| WO-2000061571-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2000-10-19 | — | — | WO | claimed |
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | disclosed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | disclosed |
| EP-1109799-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000061571-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2000-10-19 | — | — | WO | disclosed |